Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXT) Receives $10.79 Consensus PT from Analysts

Shares of Clarus Therapeutics Holdings, Inc. (NASDAQ:CRXTGet Rating) have been given an average recommendation of “Buy” by the six brokerages that are currently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $10.79.

CRXT has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Clarus Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research report on Monday, April 4th. Needham & Company LLC cut their price objective on Clarus Therapeutics from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, March 31st.

Several institutional investors have recently bought and sold shares of CRXT. Citadel Advisors LLC bought a new stake in shares of Clarus Therapeutics during the fourth quarter valued at approximately $31,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Clarus Therapeutics during the fourth quarter worth $51,000. Cowen AND Company LLC purchased a new stake in shares of Clarus Therapeutics during the third quarter valued at $53,000. Powell Investment Advisors LLC grew its holdings in shares of Clarus Therapeutics by 48.8% during the fourth quarter. Powell Investment Advisors LLC now owns 64,000 shares of the company’s stock valued at $156,000 after buying an additional 21,000 shares during the last quarter. Finally, Verition Fund Management LLC purchased a new stake in shares of Clarus Therapeutics during the third quarter valued at $160,000. 19.50% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:CRXT opened at $0.73 on Thursday. The business’s 50-day simple moving average is $1.08 and its two-hundred day simple moving average is $2.42. Clarus Therapeutics has a 52 week low of $0.53 and a 52 week high of $31.24.

Clarus Therapeutics (NASDAQ:CRXTGet Rating) last posted its quarterly earnings results on Wednesday, March 30th. The company reported ($0.19) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.68) by $0.49. As a group, analysts predict that Clarus Therapeutics will post -2.02 earnings per share for the current fiscal year.

About Clarus Therapeutics (Get Rating)

Clarus Therapeutics Holdings, Inc, a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans.

Read More

Analyst Recommendations for Clarus Therapeutics (NASDAQ:CRXT)

Receive News & Ratings for Clarus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clarus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.